148: 1239–1240 doi:10.1126/ science.148.3674.1239
ГЛАВА 9
Marquart, J., Chen, E.Y. and Prasad V. (2018) Estimation of the percentage of US patients with cancer who benefit from genome-driven oncology, JAMA Oncol. 4: 1093–1098 doi:10.1001/jamaoncol.2018.1660
Abola, M.V., Prasad, V. (2016) The use of superlatives in cancer research, JAMA Oncol. 2: 139–141 doi:10.1001/ jamaoncol.2015.3931
Kuderer, N. M., Burton, K. A., Blau, S. et al. (2017) Comparison of 2 commercially available next-generation sequencing platforms in oncology, JAMA Oncology 3: 996–998 doi:10.1001/jamaoncol.2016.4983
Prahallad, A., Sun, C., Huang, S. et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature 483: 100–103 doi:10.1038/nature10868
Prasad V. (2017) Overestimating the benefit of cancer drugs, JAMA Oncol. 3: 1737–1738 doi: 10.1001/jamaoncol.2017.0107
Salas-Vega, S., Iliopoulos, O. and Mossialos, E. (2017) Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines, JAMA Oncol. 3: 382–390 doi:10.1001/jamaoncol.2016.4166
Fojo, T., Mailankody, S. and Lo, A. (2014) Unintended consequences of expensive cancer therapeutics – the pursuit of marginal indications and a Me-Too mentality that stifles innovation and creativity: The John Conley Lecture, JAMA Otolaryngol Head Neck Surg. 140:1225–1236 doi:10.1001/ jamaoto.2014.1570
Lomangino, K. (2017) 'Not statistically significant but clinically meaningful': A researcher calls 'BS' on cancer drug spin, Health News Review (published online 24 March 2017) bit.ly/35riDTq
Oyedele, A. (2014) 19 of the Most Expensive Substances In the World, Business Insider (published online 22 September 2014) bit.ly/36kqx1W
Kim, C. and Prasad, V. (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals, JAMA Intern Med. 175: 1992–4 doi:10.1001/jamainternmed.2015.5868
Prasad, V., McCabe, C. and Mailankody, S. (2018) Low-value approvals and high prices might incentivize ineffective drug development, Nat Rev Clin Oncol 15: 399–400 doi:10.1038/ s41571–018–0030–2
Prasad, V. and Mailankody, S. (2017) Research and development spending to bring a single cancer drug to market and revenues after approval, JAMA Intern Med. 177: 1569–1575 doi:10.1001/jamainternmed.2017.3601
Prasad, V. (2016) Perspective: The precision-oncology illusion, Nature 537: S63 doi:10.1038/537S63a
Perelson, A.S., Neumann, A.U., Markowitz, M. et al (1996) HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time,